News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment and Commercial Application Programs
November 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced a two-prong CFS clinical mission for November and December 2009.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
CDC
CDC Left Leaderless Again After Acting Director Departs HHS
February 16, 2026
·
1 min read
·
Tristan Manalac
Complete response letters
FDA Rejects Disc’s Rare Blood Disease Drug Amid Reports of Prasad’s Skepticism
February 16, 2026
·
3 min read
·
Tristan Manalac
Government
‘Just Agree to It:’ Pazdur Said He Was Told To Cosign FDA’s Reduced Trial Requirements
February 16, 2026
·
2 min read
·
Tristan Manalac
Earnings
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation
February 13, 2026
·
5 min read
·
Annalee Armstrong
